---
title: "IMVT: IMVT-1402 targets major autoimmune diseases with best-in-class efficacy and broad clinical reach"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295104301.md"
description: "IMVT-1402 is advancing as a potentially first- and best-in-class anti-FcRn therapy for multiple autoantibody-driven diseases, with deep IgG reduction, convenient self-administration, and a robust clinical program targeting significant unmet needs in Graves' disease, MG, CIDP, RA, SjD, and CLE. Key data readouts and potential commercial launch are supported by strong financials.Original document: Immunovant, Inc. [IMVT] Slides Release — Aug. 6 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-08-06T11:55:32.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295104301.md)
  - [en](https://longbridge.com/en/news/295104301.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295104301.md)
generator: "portal-rs"
---

# IMVT: IMVT-1402 targets major autoimmune diseases with best-in-class efficacy and broad clinical reach

IMVT-1402 is advancing as a potentially first- and best-in-class anti-FcRn therapy for multiple autoantibody-driven diseases, with deep IgG reduction, convenient self-administration, and a robust clinical program targeting significant unmet needs in Graves' disease, MG, CIDP, RA, SjD, and CLE. Key data readouts and potential commercial launch are supported by strong financials.

Original document: Immunovant, Inc. \[IMVT\] Slides Release — Aug. 6 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [IMVT.US](https://longbridge.com/en/quote/IMVT.US.md)

## Related News & Research

- [Bank of New York Mellon Corp Acquires New Stake in Immunovant, Inc. $IMVT](https://longbridge.com/en/news/297746838.md)
- [Immunovant director Atul Pande disposes of 1,500 common shares worth $64,905](https://longbridge.com/en/news/297366091.md)
- [DWTX: Halneuron shows promise as a scalable, effective CINP therapy with strong Phase 2 results](https://longbridge.com/en/news/297686345.md)
- [Algert Global LLC Raises Position in Immunovant, Inc. $IMVT](https://longbridge.com/en/news/297139502.md)
- [Fate Therapeutics Expands Into Autoimmune Disease With New FT839 Trial](https://longbridge.com/en/news/297812155.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**